08 Apr Mithridion to release Alzheimer drug test results
MADISON – A Madison-based biopharmaceutical firm will today release the results of a drug it is testing that will stop the progression of Alzheimer’s disease. Mithridion Inc., has completed Phase I of its clinical trial for MCD-386, an M1 drug that has the potential to improve memory and cognition symptoms in Alzheimer’s patients. Results will be presented from the BioVentures Conference in Napa, California.
In commenting on results of Phase I, Mithridion CEO Trevor M. Twose stated, “We are very encouraged that we fully met our objectives for this study, and are confident that the combination of the good selectivity for M1-muscarinic action seen in preclinical testing and a controlled release formulation will provide the desired therapeutic action and good safety profile for a first-in-class therapeutic. In addition to MCD-386, Mithridion is developing a pipeline of products for CNS disorders.”
The first phase of the study was conducted at the Jasper Clinic in Kalamazoo, Michigan using a randomized, double-blind, placebo-controlled, ascending single dose trial conducted in 24 healthy volunteers, 18 of which received the drug. The tests evaluated the safety, tolerability and pharmacokinetics of MCD-386. Test showed that the drug was rapidly absorbed, reaching maximum serum concentrations in one to one and a half hours, and serum concentrations were linearly related to dose.
The company plans to evaluate the safety, tolerability and pharmacokinetics of MCD-386 in a randomized, double-blind, placebo controlled, ascending multiple-dose Phase I study to commence in the fourth quarter of 2009.